Humana Closes the Kindred Chapter With $900 Million Gentiva Exit

Humana Inc. HUM recently agreed to sell all, or substantially all, of its remaining minority stake in Gentiva, the hospice and palliative care company that emerged from the restructuring of Kindred at Home’s hospice and personal care operations. The transaction values Humana’s stake at roughly $900 million and is expected to close in the third quarter of 2026.The move completes a strategy Humana set in motion after acquiring Kindred at Home in 2021 and later spinning off non-core hospice and personal care assets. Gentiva has since grown into one of the largest end-of-life care providers in the United States. It operates at more than 430 locations across 35 states and employs over thousands of caregivers and associates.The minority stake sale to a consortium of investors marks the final step in Humana’s multiyear effort to exit ownership of businesses outside its core health insurance and home-health strategy. It simplifies the company’s portfolio, unlocks capital from a mature investment, and sharpens management’s focus on areas where Humana sees stronger long-term strategic value.Management said the cash will be used for general corporate purposes. Importantly, Humana does not expect the divestiture to have a material impact on its 2026 earnings, suggesting the Gentiva stake was not a major contributor to current profitability. Gentiva Hospice generated revenues of $2.1 billion in 2025, which led to a net loss of $84 million.HUM’s Price PerformanceHumana’s shares have gained 42.3% year to date compared with the 24.7% rise of the industry it belongs to. Image Source: Zacks Investment ResearchZacks Rank & Stocks to ConsiderHumana currently carries a Zacks Rank #3 (Hold).Some better-ranked stocks in the broader Medical space are Biodesix, Inc. BDSX, Molina Healthcare, Inc. MOH and Pediatrix Medical Group, Inc. MD, each carrying a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.The Zacks Consensus Estimate for Biodesix’s full-year 2026 earnings implies a 36% improvement from the year-ago reported figure. It has remained stable over the past 30 days. Over the last four quarters, BDSX beat earnings estimates thrice and missed once, with an average surprise of 25.6%.The consensus estimate for Molina Healthcare’s 2026 full-year earnings is pegged at $5.23 per share, which has witnessed five upward estimate revisions over the past 60 days against no downward movement. The consensus mark for MOH’s current-year revenues is pegged at $44.07 billion.The Zacks Consensus Estimate for Pediatrix Medical’s 2026 bottom line suggests 9.3% year-over-year growth. MD has witnessed three upward estimate revisions over the past 60 days against no movement in the opposite direction. It beat earnings estimates in three of the last four quarters and missed once, with an average surprise of 21.3%.7 Best Stocks for the Next 30 DaysJust released: Experts distill 7 elite stocks from the current list of 220 Zacks Rank #1 Strong Buys. They deem these tickers "Most Likely for Early Price Pops."Since 1988, the full list has beaten the market more than 2X over with an average gain of +23.7% per year. So be sure to give these hand picked 7 your immediate attention. See them now >>This article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks Weiter zum vollständigen Artikel bei Zacks